Rhopressa  (U.S.N.L.M.)
Dosing 1 drop in the evening
Chem Specs netarsudil dimesylate 0.02%
Quantities 2.5ml
Cost 341.88
Class Rho kinase1 and norepinephrine transporter inhibitor.
Action Increases trabecular outflow and decreases aqueous production.
Usage Indicated for lowering IOP with open-angle glaucoma or ocular hypertension.
IOP reduction similar (or slightly less) than latanaprost.
When used in combination with latanaprost the number of patients achieving
30% IOP reduction increases from 40% to 65%.
Side Effects Mild conjunctival hyperemia occurs in 50% to 60%, but is consistently observed in only
10% and so is considered "well tolerated". Corneal epithelial macrocysts, small conjunctival
hemorrhages, and cornea verticillata(20%) which resolve on discontinuation have been reported.
Contraindications None
Pediatric use Safety and effectiveness in pediatric patients have not been established.
Pregnancy Rat embryofetal lethality shown at 126 times normal human dose but not at 40x.
If used concomitantly with other drops, administer each at least 5 minutes apart.
BAK 0.015%
1. Rho protein kinase is a catalyst involved in cell migration and tight cell junction regulation.     N.L.M. DailyMed page for Rhopressa